Camp4 Therapeutics Corp (CAMP) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Camp4 Therapeutics reported revenue of $3.5M, up 436.5% from $652,000 the year before. Net income was -$80.4M (a -2298.5% net margin), or -$2.65 per diluted share. Operating margin was -1502.4%. Operating activities generated -$29.6M of cash, leaving -$29.9M of free cash flow. At fiscal year end, Camp4 Therapeutics held $117.8M in total assets against $70.1M in total liabilities, including $109.5M of cash and equivalents.
Open the full interactive Camp4 Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Camp4 Therapeutics Key Stats
| Share Price | $3.43 |
|---|---|
| Market Cap | $198.7M |
| Revenue YoY Growth | +436.5% |
| 52-Week Range | $2.90 – $7.13 |
| Shares Outstanding | 57.9 million (basic, 2026 Q2) |
Camp4 Therapeutics Income Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Revenue | $652,000 | $3.5M |
| Operating Income | -$53.1M | -$52.6M |
| Pre-Tax Income | -$51.8M | -$80.4M |
| Income Tax | $0 | $0 |
| Net Income | -$51.8M | -$80.4M |
| Diluted EPS | -$11.04 | -$2.65 |
Camp4 Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $795,000 | $348,000 | $1.3M | $1.8M |
| Net Income | -$15.1M | -$40.3M | -$18.3M | -$33.5M |
| Diluted EPS | -$0.55 | -$1.33 | -$0.32 | -$0.58 |
Camp4 Therapeutics Balance Sheet
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash & Equivalents | $64.0M | $109.5M |
| Current Assets | $66.4M | $114.1M |
| Total Assets | $78.3M | $117.8M |
| Current Liabilities | $9.6M | $15.5M |
| Total Liabilities | $15.2M | $70.1M |
| Shareholders' Equity | $63.1M | $47.7M |
Camp4 Therapeutics Cash Flow Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash From Operations | -$45.6M | -$29.6M |
| Cash From Investing | -$441,000 | -$243,000 |
| Cash From Financing | $71.7M | $75.9M |
| Free Cash Flow | -$46.0M | -$29.9M |
Figures from Camp4 Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Camp4 Therapeutics financials page for every line item.
Camp4 Therapeutics Company Profile
| Ticker | CAMP |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Watertown, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001736730 |
Frequently Asked Questions
What was Camp4 Therapeutics' revenue in fiscal 2025?
Camp4 Therapeutics (CAMP) reported revenue of $3.5M for fiscal 2025.
What was Camp4 Therapeutics' net income in fiscal 2025?
Camp4 Therapeutics reported net income of -$80.4M for fiscal 2025.
What was Camp4 Therapeutics' earnings per share (EPS) in fiscal 2025?
Camp4 Therapeutics' diluted EPS was -$2.65 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Camp4 Therapeutics generate in fiscal 2025?
Camp4 Therapeutics generated -$29.9M of free cash flow in fiscal 2025.
What was Camp4 Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Camp4 Therapeutics reported revenue of $1.8M.
How many shares of Camp4 Therapeutics are outstanding?
Camp4 Therapeutics reported a weighted average of 57.9 million basic shares outstanding in 2026 Q2.
What is Camp4 Therapeutics' market cap?
Based on its latest closing price, Camp4 Therapeutics (CAMP) has a market capitalization of about $198.7M.
When does Camp4 Therapeutics' fiscal year end?
Camp4 Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Camp4 Therapeutics headquartered?
Camp4 Therapeutics lists its business address in Watertown, Massachusetts in its SEC filings.